Abstract
In Nigeria, as in many low-income countries, private commercial providers play an important role in the treatment of malaria. To design effective interventions for improved access to accurate diagnosis and effective malaria treatment, there is a need to understand retailers’ behaviour and identify the factors that influence their stocking and pricing decisions. Private commercial retailers are the last link in a chain of manufacturers, importers and wholesalers, and their supply sources are likely to have an important influence on the price and quality of malaria treatment that consumers can access. However, there is limited rigorous evidence on the structure and operation of the distribution chain for antimalarial drugs that serves the retail sector.
The ACTwatch Supply Chain Study, one of the ACTwatch project components, aims to address this gap by conducting quantitative and qualitative studies on distribution chains for antimalarials in the ACTwatch countries (Nigeria, Cambodia, Benin, the Democratic Republic of Congo, Madagascar, Uganda and Zambia). This report presents the results from qualitative interviews with antimalarial drug wholesalers, retailers and other key stakeholders conducted in Nigeria between July and September 2009. A summary of the key findings is given below. To provide a complete description of the supply chain for antimalarial drugs in Nigeria, this report should be read in conjunction with the report on the results of the quantitative supply chain survey also conducted as part of this study [1], available at www.actwatch.info.
File Info

A Qualitative Assessment of the Private Sector Antimalarial Distribution Chain in Nigeria, 2009
ACTwatch, London School of Hygiene & Tropical Medicine, PSI / Population Services International, SFH / Society for Family Health
Arogundade Ekundayo, Goodman Catherine, Hanson Kara, Kiefer Sabine, O'Connell Kathryn A, Palafox Benjamin, Patouillard Edith, Tougher Sarah